Cervical Cancer – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Cervical Cancer – Pipeline Review, H2 2020’, provides an overview of the Cervical Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cervical Cancer

– The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects

– The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Aadi Bioscience Inc

AbbVie Inc

Abion Inc

Abivax SA

Advaxis Inc

Advenchen Laboratories LLC

Adze Biotechnology Inc

Affimed GmbH

Agenus Inc

Akeso Inc

Almac Discovery Ltd

Alphamab Oncology

amcure GmbH

Andes Biotechnologies

Anew Oncology Inc

Anteris Technologies Ltd

AntiCancer Inc

Apimeds Inc

Apollomics Inc

Apotex Inc

Asana BioSciences LLC

Ascenta Therapeutics Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Beijing Neoantigen Biotechnology Co Ltd

Table of Contents

Table of Contents

Introduction

Cervical Cancer - Overview

Cervical Cancer - Therapeutics Development

Cervical Cancer - Therapeutics Assessment

Cervical Cancer - Companies Involved in Therapeutics Development

Cervical Cancer - Drug Profiles

Cervical Cancer - Dormant Projects

Cervical Cancer - Discontinued Products

Cervical Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Cervical Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Cervical Cancer – Pipeline by 3SBio Inc, H2 2020

Cervical Cancer – Pipeline by Aadi Bioscience Inc, H2 2020

Cervical Cancer – Pipeline by AbbVie Inc, H2 2020

Cervical Cancer – Pipeline by Abion Inc, H2 2020

Cervical Cancer – Pipeline by Abivax SA, H2 2020

Cervical Cancer – Pipeline by Advaxis Inc, H2 2020

Cervical Cancer – Pipeline by Advenchen Laboratories LLC, H2 2020

Cervical Cancer – Pipeline by Adze Biotechnology Inc, H2 2020

Cervical Cancer – Pipeline by Affimed GmbH, H2 2020

Cervical Cancer – Pipeline by Agenus Inc, H2 2020

Cervical Cancer – Pipeline by Akeso Inc, H2 2020

Cervical Cancer – Pipeline by Almac Discovery Ltd, H2 2020

Cervical Cancer – Pipeline by Alphamab Oncology, H2 2020

Cervical Cancer – Pipeline by amcure GmbH, H2 2020

Cervical Cancer – Pipeline by Andes Biotechnologies, H2 2020

Cervical Cancer – Pipeline by Anew Oncology Inc, H2 2020

Cervical Cancer – Pipeline by Anteris Technologies Ltd, H2 2020

Cervical Cancer – Pipeline by AntiCancer Inc, H2 2020

Cervical Cancer – Pipeline by Apimeds Inc, H2 2020

Cervical Cancer – Pipeline by Apollomics Inc, H2 2020

Cervical Cancer – Pipeline by Apotex Inc, H2 2020

Cervical Cancer – Pipeline by Asana BioSciences LLC, H2 2020

Cervical Cancer – Pipeline by Ascenta Therapeutics Inc, H2 2020

Cervical Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2020

Cervical Cancer – Pipeline by AstraZeneca Plc, H2 2020

Cervical Cancer – Pipeline by Bayer AG, H2 2020

Cervical Cancer – Pipeline by BeiGene Ltd, H2 2020

Cervical Cancer – Pipeline by Beijing Neoantigen Biotechnology Co Ltd, H2 2020

Cervical Cancer – Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, H2 2020

Cervical Cancer – Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, H2 2020

Cervical Cancer – Pipeline by BioAtla LLC, H2 2020

Cervical Cancer – Pipeline by Biocad, H2 2020

Cervical Cancer – Pipeline by BIOCND Inc, H2 2020

Cervical Cancer – Pipeline by Biocon Ltd, H2 2020

Cervical Cancer – Pipeline by BioIntegrator Ltd, H2 2020

Cervical Cancer – Pipeline by Bioleaders Corp, H2 2020

Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd, H2 2020

Cervical Cancer – Pipeline by BioNTech SE, H2 2020

Cervical Cancer – Pipeline by Biotheus Inc, H2 2020

Cervical Cancer – Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Cervical Cancer – Pipeline by Bristol-Myers Squibb Co, H2 2020

Cervical Cancer – Pipeline by Celleron Therapeutics Ltd, H2 2020

Cervical Cancer – Pipeline by Cellestia Biotech AG, H2 2020

Cervical Cancer – Pipeline by Cellid Co Ltd, H2 2020

Cervical Cancer – Pipeline by Centus Biotherapeutics Ltd, H2 2020

Cervical Cancer – Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020

Cervical Cancer – Pipeline by Chengdu Institute of Biological Products Co Ltd, H2 2020

Cervical Cancer – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2020

Cervical Cancer – Pipeline by Clovis Oncology Inc, H2 2020

Cervical Cancer – Pipeline by Convert Pharmaceuticals SA, H2 2020

Cervical Cancer – Pipeline by Corvus Pharmaceuticals Inc, H2 2020

Cervical Cancer – Pipeline by Cotinga Pharmaceuticals Inc, H2 2020

Cervical Cancer – Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020

Cervical Cancer – Pipeline by Cue Biopharma Inc, H2 2020

Cervical Cancer – Pipeline by Cytocom Inc, H2 2020

Cervical Cancer – Pipeline by CytomX Therapeutics Inc, H2 2020

Cervical Cancer – Pipeline by CZ BioMed Corp, H2 2020

Cervical Cancer – Pipeline by Daewon Pharmaceutical Co Ltd, H2 2020

Cervical Cancer – Pipeline by Daiichi Sankyo Co Ltd, H2 2020

Cervical Cancer – Pipeline by Disulfican Ltd, H2 2020

Cervical Cancer – Dormant Projects, H2 2020

Cervical Cancer – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Cervical Cancer, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports